Skip to main content
XGN
NASDAQ Industrial Applications And Services

Exagen Registers $150M Shelf With $50M TD Cowen ATM, ~34% Dilution at $5.81

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$5.83
Mkt Cap
$139.538M
52W Low
$2.59
52W High
$10.27
52W Position info
125% above low
Off High info
43% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

XGN has more than doubled off its 52-week low of $2.59 on light trading volume (0.3× avg).

Summary

Exagen registered a $150 million shelf, including a $50 million at-the-market stock program with TD Cowen that would add 8,605,852 shares — about a third more than the 25,420,340 outstanding — if fully sold at $5.81. No shares have been sold under the program yet.


Key Events · Financing and Capital Events · XGN

  • $50M ATM Registered With TD Cowen

    A November 9, 2026 sales agreement lets Exagen sell up to $50.0 million of common stock from time to time through TD Cowen; no sales have been made under the agreement yet.

  • Roughly a Third More Shares at $5.81

    At the $5.81 last reported sale price, full use of the ATM means 8,605,852 new shares against 25,420,340 outstanding at September 30, 2026 — about 33.9% dilution, or $3.98 per share immediate dilution to new buyers.

  • Agent Fees and Offering Costs

    TD Cowen earns 3.0% of gross proceeds, Exagen reimburses up to $75,000 of the agent's legal expenses, and total offering expenses are estimated at about $125,000 excluding commissions.

  • Perceptive Tranche B Cut and Drawn

    Amendments on October 19 and November 9, 2026 reduced Tranche B from $10.0 million to $5.0 million and extended availability to November 15, 2026; Exagen drew the $5.0 million on November 9, 2026.


Analysis · XGN · Industrial Applications And Services

Exagen is putting real numbers on the capital raise it flagged in this morning's 10-Q. The $50.0 million at-the-market program through TD Cowen is now fully registered and can be sold into the market at any time; at the $5.81 last reported sale price, full use would mean 8,605,852 new shares — roughly a third more stock than the 25,420,340 shares outstanding at September 30, 2026. That is meaningful dilution for a company that ended the quarter with $28.1 million in cash and a $6.3 million quarterly net loss, but it also gives management a live funding tap without another negotiated deal. The filing also confirms the Perceptive credit amendments: Tranche B was cut from $10.0 million to $5.0 million and extended to November 15, 2026, and the company drew the $5.0 million on November 9, 2026, which vested 75,000 warrant shares while 450,000 remain subject to future vesting. Nothing has been sold under the ATM yet — this is capacity, not proceeds.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XGN was trading at $5.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $139.5M. The 52-week trading range was $2.59 to $10.27. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XGN - Latest Insights

XGN
Nov 10, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.55
Real-time Price: $5.72 info
Change: -$0.829 (-13%) info
Market Cap: $139.78M info
XGN
Nov 10, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.59
Real-time Price: $5.72 info
Change: -$1.87 (-25%) info
Market Cap: $139.78M info
XGN
Aug 04, 2026, 9:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.66
Real-time Price: $5.72 info
Change: +$0.061 (+1%) info
Market Cap: $139.78M info
XGN
Aug 04, 2026, 8:12 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.60
Real-time Price: $5.72 info
Change: +$0.121 (+2%) info
Market Cap: $139.78M info
XGN
Aug 04, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.21
Real-time Price: $5.72 info
Change: +$0.511 (+10%) info
Market Cap: $139.78M info